Muscovy duck parvovirus and gosling plague bivalent vaccine

A technology of muscovy duck parvovirus and double inactivated vaccine, which is applied in the direction of vaccines, viruses, antiviral agents, etc., can solve the problems of reduced vaccine potency, achieve good immunogenicity, good safety, and prevent young muscovy ducks Effects of Parvovirus and Gosling Plague Virus Infection

Active Publication Date: 2016-09-07
YEBIO BIOENG OF QINGDAO
View PDF4 Cites 5 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Moreover, due to the reduction of the potency of the vaccine used due to virus mutation, it is also necessary to screen out the mutated virus strain to prepare a vaccine with higher efficacy

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Muscovy duck parvovirus and gosling plague bivalent vaccine
  • Muscovy duck parvovirus and gosling plague bivalent vaccine
  • Muscovy duck parvovirus and gosling plague bivalent vaccine

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0017] Example 1 Muscovy duck parvovirus seedling strain (YBMDP) screening

[0018] 1. Screening of YBMDP strain In 2011, an acute muscovy duck parvovirus disease broke out from a duck farm in Zhejiang Province. The pancreas and intestines of dead ducks were taken, and the pancreas and intestinal tissues were homogenized with non-normal saline to make 20 % suspension, centrifuged at 3000r / min for 15min, took the cleared bacteria and inoculated 13-day-old muscovy duck embryos through the allantoic cavity respectively, hatched for 120 hours, collected allantoic fluid and embryo body tissue, after homogenization, repeated freezing and thawing for 3 The second time, the supernatant was taken and frozen. After the harvested virus liquid was purified, the virus characteristics of the virus content, immunogenicity, specificity and purity were analyzed and tested, and the results showed that the virus content of the strain was 10 5.7 ELD 50 / 0.2ml, the minimum immune dose is 10 2.0...

Embodiment 2

[0027] Example 2 Preparation of vaccine

[0028] 1. Preparation of virus liquid for seedling production

[0029] 1.1 Preparation of virus liquid of YBMDP strain Dilute the YBMDP strain, the virus species used for production, 100 times with sterile saline, inoculate 11-12 day-old susceptible muscovy duck embryos in the allantoic cavity, 0.2ml per embryo, incubate at 37°C, 2 The next step is to check the embryo. Select duck embryos that died within 48 to 168 hours after inoculation, place them at 2 to 8°C for 4 to 12 hours, open the air chamber under sterile conditions, and pick out embryos with extensive hemorrhage, hair follicle hemorrhage, liver degeneration and necrosis, and chorioallantois For embryos with mild edema, take the embryo body (remove the head and limbs) and put it into a tissue grinder to crush, collect allantoic fluid and amniotic fluid, homogenate with embryo fluid, take the crushed tissue and add it in a ratio of 1:1 Physiological saline was mixed, freeze-...

Embodiment 3

[0054] 1. Preparation of antigens for seedling production

[0055] 1. Preparation of virus liquid for seedling production

[0056] 1.1 Dilute the YBMDP strain, the virus species used for production, 100 times with sterile saline, inoculate 11-12 day-old susceptible muscovy duck embryos into the allantoic cavity, 0.2ml per embryo, incubate at 37°C, and inspect the embryos twice a day. Select duck embryos that died within 48 to 168 hours after inoculation, place them at 2 to 8°C for 4 to 12 hours, open the air chamber under sterile conditions, and pick out embryos with extensive hemorrhage, hair follicle hemorrhage, liver degeneration and necrosis, and chorioallantois For embryos with mild edema, take the embryo body (remove the head and limbs) and put it into a tissue grinder to crush, collect allantoic fluid and amniotic fluid, homogenate with embryo fluid, take the crushed tissue and add it in a ratio of 1:1 Physiological saline was mixed, freeze-thawed 3 times, centrifuged ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
diameteraaaaaaaaaa
diameteraaaaaaaaaa
Login to view more

Abstract

The invention provides a Muscovy duck parvovirus and gosling plague bivalent vaccine. The antigens used by the vaccine is inactivated Muscovy duck parvoviruses and Muscovy duck-source gosling plague viruses, the preservation number of the Muscovy duck parvoviruses is CGMCC No. 8504, and the preservation number of the Muscovy duck-source gosling plague viruses is CCTCC No. V201620. A preparation method of the Muscovy duck parvovirus and gosling plague bivalent vaccine includes: the Muscovy duck parvovirus YBMDP strains and Muscovy duck-source gosling plague virus YBGPV-M strains which are high in virus content and good in immunogenicity are screened, infected embryos and allantoic fluid are collected after duck embryo inoculation, and oil emulsion adjuvant is added for emulsification and mixing to obtain the vaccine after homogenization, ultrafiltration and concentration, and formaldehyde solution inactivation. The prepared vaccine can immunize breeding Muscovy ducks and increase the level of two types of antibodies of the breeding Muscovy ducks at the same time, guarantee the offspring maternal antibody level of the breeding Muscovy ducks, and prevent the young Muscovy duck parvovirus diseases caused by the Muscovy duck parvoviruses and gosling plague virus infection caused by the Muscovy duck-source gosling plague viruses.

Description

technical field [0001] The invention belongs to the technical field of poultry pathogenic microorganism screening, and in particular relates to the preparation and application of a dual-inactivated vaccine for muscovy duck parvovirus and gosling plague. Background technique [0002] Muscovy duck parvovirus disease is an acute or subacute infectious disease that affects young muscovy ducks. It is an infectious disease mainly characterized by panting, diarrhea, pancreatic necrosis and hemorrhage; it is highly contagious, and its morbidity and mortality are high. Very high, often causing serious economic losses. The disease mainly occurs in young muscovy ducks of 1 to 3 weeks of age, especially young muscovy ducks of about 10 days of age. The disease first appeared in Fujian, China, and the Brittany region of western France in the mid-to-late 1980s, and it was recognized as an independent disease different from gosling plague in the early 1990s. [0003] Goose parvovirus dise...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K39/23A61P31/20
CPCA61K39/12A61K2039/5252A61K2039/552A61K2039/70C12N2750/14334Y02A50/30
Inventor 邹敏吴发兴张志鸿朱艳梅孙健刘蕾
Owner YEBIO BIOENG OF QINGDAO
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap